Sponsored by
Researchers at CoSyne Therapeutics have discovered that glioma cells with non-mutant (wild-type) TP53 AND RB1 genes may be sensitive to cytarabine, which is a chemotherapy drug already approved for intrathecal injection in certain types of leukemia involving the brain and spinal fluid.
This finding suggests that cytarabine could be worth further study in patients with leptomeningeal spread of glioma, where chemotherapy is sometimes administered directly into the spinal fluid. CoSyne is interested in collecting case reports from patients who have both malignant glioma and leptomeningeal disease to better understand responses and tolerability in this rare condition.
If you have this condition, it might be worth checking your pathology report for TP53 and RB1 genes. If they are wildtype (not mutated), this may be an accessible option for you. If you or your medical care team would like to learn more about this research effort, please sign up for our patient navigation program here.